


DOCKET NO.: 241019US0DIV



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Rossella MUSA et al

SERIAL NO.: 10/628,453

GROUP ART UNIT: 1618

FILED: July 29, 2003

EXAMINER: OH, S. J.

FOR: MODIFIED CARRIER PARTICLES FOR USE IN DRY POWDER INHALERS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicants wish to disclose the following information.

REFERENCES

- ☒ The Applicants wish to make of record the references listed on the attached Form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ A check or credit card payment form is attached in the amount required under 37 C.F.R. §1.17(p).

RELATED CASES

- ☐ Attached is a list of Applicants' pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 C.F.R. §1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached Form PTO-1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 C.F.R. §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

05/17/2006 HALI11 00000087 10628453

02 FC:1806

180.00 OP


Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)


Stephen G. Baxter

Registration No. 32,884



Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 241019US0DIV		SERIAL NO. 10/628,453	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Rossella MUSA et al			
				FILING DATE July 29, 2003		GROUP 1618	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO						
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	Herbert A. LIEBERMAN et al, <u>Pharmaceutical Dosage Forms</u> , Volume 2, 1981, Marcel Dekker, Inc., pp. 29-43.					
	AX						
	AY						
	AZ					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							